Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/18/21 (What's New)

Summary

  • Raltegravir was the first INSTI to be approved for the treatment of HIV infection and has been studied extensively as part of regimens for treatment-experienced patients[Steigbigel 2008]
  • It has been studied as a switch regimen primarily to improve tolerability but is currently less favored than other INSTIs because it is administered twice daily and has a lower barrier to resistance than dolutegravir or bictegravir/emtricitabine/tenofovir AF
  • Studies evaluating switches in suppressed patients receiving stable lopinavir/ritonavir-based antiretroviral therapy switched to raltegravir found improvements in serum lipids

    Action required

    Keywords: Switch Strategies

    ©2020 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.